Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Irene Modesto

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Inflammatory Bowel Diseases|November 9, 2025
Machine Learning Models for the Assessment of the Mayo Endoscopic Score in Ulcerative Colitis Trial Endpoints: A Systematic ReviewDavid T Rubin, Walter Reinisch, Neeraj Narula, et al.
Journal of Crohn'S & Colitis|July 4, 2023
Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical ProgrammeStefan Schreiber, David T Rubin, Siew C Ng, et al.
Journal of Crohn'S & Colitis|May 3, 2024
Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical ProgrammeMiguel Regueiro, Britta Siegmund, Andres J Yarur, et al.
BMJ Open Gastroenterology|January 8, 2025
Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitisSéverine Vermeire, David T Rubin, Laurent Peyrin-Biroulet, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 5, 2021
COVID-19 Outcomes Among Racial and Ethnic Minority Individuals With Inflammatory Bowel Disease in the United StatesManasi Agrawal, Erica J Brenner, Joyce Wing Yan Mak, et al.
Journal of Crohn'S & Colitis|April 13, 2024
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical ProgrammeLaurent Peyrin-Biroulet, Marla C Dubinsky, Bruce E Sands, et al.
Journal of Crohn'S & Colitis|February 4, 2023
Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential SolutionsMathieu Uzzan, Yoram Bouhnik, Maria Abreu, et al.
Microorganisms|November 19, 2020
Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in ItalyMarco Canzoni, Massimo Marignani, Maria Laura Sorgi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 5, 2026
The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results from the Phase 2 GLADIATOR TrialSilvio Danese, Martina Goetsch, Laurent Peyrin-Biroulet, et al.
Journal of Crohn'S & Colitis|June 15, 2024
Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 TrialsSéverine Vermeire, Bruce E Sands, Laurent Peyrin-Biroulet, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Inflammatory Bowel Diseases|November 9, 2025
Machine Learning Models for the Assessment of the Mayo Endoscopic Score in Ulcerative Colitis Trial Endpoints: A Systematic ReviewDavid T Rubin, Walter Reinisch, Neeraj Narula, et al.
Journal of Crohn'S & Colitis|July 4, 2023
Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical ProgrammeStefan Schreiber, David T Rubin, Siew C Ng, et al.
Journal of Crohn'S & Colitis|May 3, 2024
Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical ProgrammeMiguel Regueiro, Britta Siegmund, Andres J Yarur, et al.
BMJ Open Gastroenterology|January 8, 2025
Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitisSéverine Vermeire, David T Rubin, Laurent Peyrin-Biroulet, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 5, 2021
COVID-19 Outcomes Among Racial and Ethnic Minority Individuals With Inflammatory Bowel Disease in the United StatesManasi Agrawal, Erica J Brenner, Joyce Wing Yan Mak, et al.
Journal of Crohn'S & Colitis|April 13, 2024
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical ProgrammeLaurent Peyrin-Biroulet, Marla C Dubinsky, Bruce E Sands, et al.
Journal of Crohn'S & Colitis|February 4, 2023
Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential SolutionsMathieu Uzzan, Yoram Bouhnik, Maria Abreu, et al.
Microorganisms|November 19, 2020
Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in ItalyMarco Canzoni, Massimo Marignani, Maria Laura Sorgi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 5, 2026
The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results from the Phase 2 GLADIATOR TrialSilvio Danese, Martina Goetsch, Laurent Peyrin-Biroulet, et al.
Journal of Crohn'S & Colitis|June 15, 2024
Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 TrialsSéverine Vermeire, Bruce E Sands, Laurent Peyrin-Biroulet, et al.
Pageof 5